


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Date: 26.10.2021

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir/Madam,

**SUB: SUBMISSION OF RECONCILIATION OF SHARE CAPITAL AUDIT REPORT FOR
THE QUARTER ENDED ON 30.09.2021**

With reference to the above, please find enclosed herewith Reconciliation of Share Capital Audit Report under provision of Regulation 55A of the SEBI (Depositories and Participants) Regulations, 1996 of the Company for the quarter ended 30.09.2021

Please find above and acknowledge the same.

Thanking You,

Yours Faithfully,
For, BIOGEN PHARMACHEM INDUSTRIES LIMITED



DIRECTOR/AUTHORISED SIGNATORY



To,
The Board of Directors,
BIOGEN PHARMACHEM INDUSTRIES LTD(FORMERLY KNOWN AS SUN TECHNO OVERSEAS LIMITED)
Rajkot

✧ Reconciliation Of Share Capital Audit Report ✧

- | 1. For Quarter Ended | 30.09.2021 | | | | |
|---|---|------------------|---------------------------|-----------|--------|
| 2. ISIN | INE703D01023 | | | | |
| 3. Face Value | Rs.1/- (Rupee One only) | | | | |
| 4. Name of the Company | Biogen Pharmachem Industries Ltd(Formerly Known As Sun Techno Overseas Limited)
CIN: L51100GJ1995PLC026702 | | | | |
| 5. Registered Office Address | Shop No. 8, First Floor, Makers-1 Building,
Jawahar Road, Rajkot-360001
E mail: suntechnooverseas@gmail.com | | | | |
| 6. Correspondence Address | ----As above---- | | | | |
| 7. Telephone & Fax Nos. | Tel.: 079-27498832 Fax: 079-26765463 | | | | |
| 8. Email Address | suntechnooverseas@gmail.com
biogenpharmachem@gmail.com | | | | |
| 9. Names of the Stock Exchanges where the company's securities are listed: | | | | | |
| BSE LIMITED, Mumbai | | | | | |
| 10. Issued Capital | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 60%;">Number of shares</th> <th style="width: 40%;">% of Total Issued Capital</th> </tr> <tr> <td>652603000</td> <td>100.00</td> </tr> </table> | Number of shares | % of Total Issued Capital | 652603000 | 100.00 |
| Number of shares | % of Total Issued Capital | | | | |
| 652603000 | 100.00 | | | | |
| 11. Listed Capital (Exchange wise) | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 60%;">Number of shares</th> <th style="width: 40%;">% of Total Issued Capital</th> </tr> <tr> <td>652603000</td> <td>100.00</td> </tr> </table> | Number of shares | % of Total Issued Capital | 652603000 | 100.00 |
| Number of shares | % of Total Issued Capital | | | | |
| 652603000 | 100.00 | | | | |
| 12. Held in dematerialized form in CDSL | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 60%;">Number of shares</th> <th style="width: 40%;">% of Total Issued Capital</th> </tr> <tr> <td>413914028</td> <td>63.43</td> </tr> </table> | Number of shares | % of Total Issued Capital | 413914028 | 63.43 |
| Number of shares | % of Total Issued Capital | | | | |
| 413914028 | 63.43 | | | | |
| 13. Held in dematerialized form in NSDL | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 60%;">Number of shares</th> <th style="width: 40%;">% of Total Issued Capital</th> </tr> <tr> <td>238677572</td> <td>36.57</td> </tr> </table> | Number of shares | % of Total Issued Capital | 238677572 | 36.57 |
| Number of shares | % of Total Issued Capital | | | | |
| 238677572 | 36.57 | | | | |
| 14. Physical | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 60%;">Number of shares</th> <th style="width: 40%;">% of Total Issued Capital</th> </tr> <tr> <td>11400</td> <td>0.00</td> </tr> </table> | Number of shares | % of Total Issued Capital | 11400 | 0.00 |
| Number of shares | % of Total Issued Capital | | | | |
| 11400 | 0.00 | | | | |
| 15. Total No. of shares (12+13+14) | 652603000 | | | | |
| 16. Reasons for difference if any, between (10&11), (10&15), (11&15) | N. A. | | | | |
| 17. Certifying the details of changes in share capital during the quarter under consideration as per Table below: | | | | | |

Particulars***	No. of shares	Applied for listing	Listing on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-principal approval Pending for SE (Specify Names)
-----N.A.-----						

***Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, forfeited, any other (to specify)



! 2 !

BIOGEN/SEPTEMBER -2021

18. Register of Members is updated (Yes / No) Yes
If not, updated upto which date --
19. Reference of previous quarter with regards to excess dematerialized shares, if any. N. A.
20. Has the Company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why? N. A.

21. Mentioned the total no of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 days	Nil	Nil	Nil
Pending for more than 21 days	Nil	Nil	Nil

22. Name, Telephone & Fax No. of the Compliance Officer of the Company

KHUSHBOO KHANDELWAL
COMPANY SECRETARY & COMPLIANCE
OFFICER
Tel. No. 079-27498832

23. Name, Address, Tel. & Fax No., Reg. No. of the Auditor

Geeta Serwani & Associates
COMPANY SECRETARY
401, Sri Ranga Appts, Opp keys High School
SD Road, Secunderabad -500025 (Telengana)
CP No. 8842, Membership No: F8991
MO: 8885536949

24. Appointment of common agency for share registry work (if yes (Name & address)

SATELLITE CORPORATE SERVICES
PRIVATE LIMITED
Office No 106-107, Dattani Plaza, East West
Compound, Andheri Kurla Road, Safedpul
Sakinaka, Mumbai, Maharashtra, 400072

25. Any other details that the auditor may like to provide. Not any.

For, GEETA SERWANI & ASSOCIATES
PRACTICING COMPANY SECRETARY

Place: Secunderabad



CS GEETA SERWANI
PROPRIETOR
C. P. NO.: 8842
MEMBERSHIP NO. F8991
Date: 25-10-2021
UDIN : F008991C001266423